Imaging, Radiation Oncology, Radiomics最新文献

筛选
英文 中文
Abstract PR10: Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic-based therapies 摘要:人肺鳞状细胞癌的多模态成像揭示了独特的代谢依赖性,这些代谢依赖性是基于代谢的治疗有效靶向的
Imaging, Radiation Oncology, Radiomics Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-PR10
M. Momčilović, D. Shackelford
{"title":"Abstract PR10: Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic-based therapies","authors":"M. Momčilović, D. Shackelford","doi":"10.1158/1557-3265.AACRIASLC18-PR10","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-PR10","url":null,"abstract":"Altered metabolism is known to commonly contribute to cancer growth, forming the conceptual basis for the development of metabolic therapies as cancer treatments. However, the specific metabolic characteristics of individual cancer types in vivo are still largely unknown, limiting the translatability of metabolic therapies in the clinic. In this study we used a multimodality imaging approach to identify metabolic dependencies in lung squamous cell carcinomas (SCC) in order to guide precise treatments with metabolic therapies. We performed in vivo metabolic profiling and molecular analysis of lung SCC using positron emission tomography (PET) imaging, liquid chromatography mass spectrometry (LC-MS), and immunohistochemistry (IHC). PET imaging lung SCC tumors with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-Glutamine PET tracers identifed a conserved metabolic reliance on both glucose and glutamine that we confirmed with LC-MS based metabolomics and quantitative IHC. The mTOR kinase is a central regulator of growth and metabolism and is readily inhibited using allosteric and catalytic kinase inhibitors. Using the mTOR catalytic kinase inhibitor MLN128, we successfully inhibited glycolysis in lung SCC. However, lung SCC tumors were able to metabolically adapt to chronic mTOR inhibition through upregulation of glutamine metabolism. We discovered that chronic mTOR inhibition induced phosphorylation and inactivation of GSK3a/b resulting in upregulation and activation of cMYC and cJUN—both central regulators of the glutaminase (GLS) enzyme and glutaminolysis. Importantly, phospho-GSK3α/β and phospho-cJUN proteins serve as functional biomarkers that predict MLN128 resistance and upregulation of glutaminolysis. To overcome MLN128 resistance we treated lung SCC tumors with the glutaminase inhibitor CB-839. The combination of MLN128 and CB-839 effectively overcame therapy resistance in genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs) of lung SCC. Lastly, data mining from The Lung Cancer Genome Atlas coupled to our PET imaging and IHC biomarkers analysis allowed us to construct a metabolic signature that is conserved in human lung SCC as well as a broad spectrum of hypermetabolic human tumors. These tumors include lung SCC, head and neck squamous cell carcinoma (HNSCC), osteosarcomas (OS), and triple-negative breast cancer (TNBC). Importantly, this metabolic signature is predictive of patient outcome and response to combined metabolic therapies targeting mTOR and glutaminase. We therefore propose a clinically translatable treatment strategy for lung SCC patients that is driven by PET imaging and IHC to first stratify patients by their metabolic signature, which is then used to guide the delivery of precise metabolic-based therapies that target key metabolic nodes such as mTOR and GLS. This abstract is also being presented as Poster B11. Citation Format: Milica Momcilovic, David B. Shackelford. Multimodality imaging of human lu","PeriodicalId":271698,"journal":{"name":"Imaging, Radiation Oncology, Radiomics","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115826508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract IA32: Multiscale modeling of lung cancer IA32:肺癌的多尺度建模
Imaging, Radiation Oncology, Radiomics Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-IA32
O. Gevaert
{"title":"Abstract IA32: Multiscale modeling of lung cancer","authors":"O. Gevaert","doi":"10.1158/1557-3265.AACRIASLC18-IA32","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-IA32","url":null,"abstract":"Vast amounts of biomedical data are now routinely available for lung cancer patients ranging from sequencing of lung tissues to liquid biopsies. In addition, new computational tools for quantitatively analyzing immunohistochemistry (IHC) and radiology images are now available. Multi-scale data is now available for complex diseases at molecular, cellular and tissue scale to establish a more comprehensive view of key biological processes. Intra and inter individual heterogeneities are often quoted as the main challenge for studying cancer. These heterogeneities exist at all scales, from microscopic to macroscopic. However, the technologies used to generate data at a particular scale don’t equally assess the heterogeneity. A single biopsy of a lung tumor does not reflect the potential cellular and spatial heterogeneity. Radiology images on the other hand provide a global picture of the heterogeneity of the complete tumor at the tissue scale. We propose multi-scale modeling to counter heterogeneity and uncover potentially untapped synergies between different data modalities by integrating information across spatial scales. Multi-scale modeling involves linking information from molecules, cells, tissues, and organs all the way to the organism and the population. We propose to use high dimensional molecular data with cellular and tissue scale image data to develop a statistical multi-scale modeling approach of cancer by tapping the previously understudied information in IHC and radiology images. For example, recent reports showed how to integrate transcriptomic data and CT images resulting in intriguing associations between gene expression signatures and CT image phenotypes. Secondly, multiple studies have shown that EGFR mutation status can be predicted from CT images features, opening up avenues for non-invasive therapy monitoring. In addition, computational analysis of IHC and radiology images is able to predict the overall survival of lung cancer patients. Each of these single reports have shown the potential of multi-scale modeling, however a complete multi-scale model of lung cancer is still under development. Overall, multi-scale modeling can have profound contributions toward predicting diagnosis and treatment by revealing synergies and previously unappreciated relationships. Multi-scale modeling also can contribute to a more fundamental understanding of lung cancer development and can reveal novel insights in how data at different scales are linked to each other. Citation Format: Olivier Gevaert. Multiscale modeling of lung cancer [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA32.","PeriodicalId":271698,"journal":{"name":"Imaging, Radiation Oncology, Radiomics","volume":"20 9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114030329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract B10: Radiomics signatures on the region defined by using multi-window CT to improve detection lung cancer screening B10:多窗CT定义区域放射组学特征,提高肺癌筛查检测水平
Imaging, Radiation Oncology, Radiomics Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-B10
Hong Lu, W. Mu, Y. Balagurunathan, Jin Qi, M. Schabath, R. Gillies
{"title":"Abstract B10: Radiomics signatures on the region defined by using multi-window CT to improve detection lung cancer screening","authors":"Hong Lu, W. Mu, Y. Balagurunathan, Jin Qi, M. Schabath, R. Gillies","doi":"10.1158/1557-3265.AACRIASLC18-B10","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-B10","url":null,"abstract":"Purpose: To evaluate the utility of defining a region using complementary information provided by different CT windows on the lung nodules to predict malignancy. Methods: We obtained 50 cases from National Lung Screening Trial (NLST) with 23 malignant and 27 benign patients. We segmented lung nodules using lung and mediastinal window independently and obtained the difference region (3D). About 260 quantitative radiomics features were exacted on the voxels segmented from different windows and the difference region. We used support vector machines (SVM) to build a predictive model to identify malignancy. We compared the effectiveness of the multi-window based features against single-lung window features using a 2-fold cross validation. Results: We find several radiomics features in the difference region to be predictive of malignancy; the best univariate features was Run_Length_Nonuniformity differnce region had an AUC of 0.911.The best feature in the lung window was defined by Sum_Entropylung window, which had an AUC of only 0.825. While using cross-validataion (2-fold) we obtained a mean accuracy of 80.97% and an AUC of 0.8 (specificity and sensitivity of 0.887 and 0.712). Compared to single-window, the best predictive features had accuracy of 78.17% and AUC of 0.772 (specificity and sensitivity of 0.876 and 0.667). Conclusions: The multi-window based radiomics features, especially the features from difference area, can improve diagnostic performance in differentiation of benign and malignant lung nodules to great extent. Citation Format: Hong Lu, Wei Mu, Yoganand Balagurunathan, Jin Qi, Mathew Schabath, Robert James Gillies. Radiomics signatures on the region defined by using multi-window CT to improve detection lung cancer screening [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr B10.","PeriodicalId":271698,"journal":{"name":"Imaging, Radiation Oncology, Radiomics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129693270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract B12: Centrosome clustering inhibition as a novel strategy to sensitize non-small cell lung cancer to radiation treatment and immunotherapy 摘要:中心体聚类抑制是一种使非小细胞肺癌对放射治疗和免疫治疗敏感的新策略
Imaging, Radiation Oncology, Radiomics Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-B12
Hailun Wang, Katriana Nugent, M. Ballew, Ghali Lemtiri-Chlieh, N. Raman, Michelle S Levine, A. Holland, P. Tran
{"title":"Abstract B12: Centrosome clustering inhibition as a novel strategy to sensitize non-small cell lung cancer to radiation treatment and immunotherapy","authors":"Hailun Wang, Katriana Nugent, M. Ballew, Ghali Lemtiri-Chlieh, N. Raman, Michelle S Levine, A. Holland, P. Tran","doi":"10.1158/1557-3265.AACRIASLC18-B12","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-B12","url":null,"abstract":"The centrosome is a microtubule-organizing center that plays an important role during M-phase and cell division where it organizes the two poles of the bipolar microtubule spindle apparatus from which chromosomes are segregated. In contrast to most normal cells, the vast majority of lung cancers contain extra copies of centrosomes, and a large body of circumstantial evidence links extra centrosomes to the development of cancer. Cells with supernumerary centrosomes form multipolar mitotic spindles, which, if not corrected, lead to lethal multipolar divisions or “mitotic catastrophe.” To overcome this, lung cancer cells cluster their centrosomes into two spindle poles, enabling tumor cells to survive. Thus, inhibition of centrosome clustering (CCi) can force cancer cells into multipolar divisions, lead to chromosomal instability, make cancer cells more sensitive to radiation treatment, and eventually result in the selective killing of cancer cells. At the same time, this approach should spare healthy tissues with normal centrosome numbers, resulting in a favorable therapeutic index. To examine the relationship between CCi and radiation-treatment sensitivity, we first treated three NSCLC cell lines (A549, H460 and H358) and one immortalized primary human bronchial epithelial cell (HBEC) with griseofulvin—a centrosomal clustering inhibitor. Immunofluorescent staining for pericentrin and alpha-tubulin, we observed a significant increase in the number of cells with multipolar spindles in NSCLC cells compared to HBECs (40-80% vs. 15%). Next, we examined the ability of griseofulvin to radiosensitize these cells to radiation treatment. By using clonogenic assays, we saw significantly less clonogenic potential of NSCLC cells following radiation treatment after exposure to 30 uM of griseofulvin, but griseofulvin did not radiosensitize HBECs. To further confirm our results, we genetically targeted KIFC1, a member of kinesin-14 family of motor proteins that have been shown to be essential for clustering centrosomes in cancer cells, but are not required for division in normal cells. In our experiments, knockdown of KIFC1 expression with siRNA also significantly sensitized NSCLC cells to radiation treatment. Finally, when we treated the NSCLC cells with griseofulvin, we saw a significant increase in the formation of micronuclei in cancer cells. Recently, it has been shown that micronuclei are important sources of immunostimulatory DNA via activation of the cGAS-STING pathway. Therefore, inhibition of CC could potentially augment immunogenicity and increase efficiency of immunotherapy (IMT). In conclusion, inhibition of CC resulted in the formation of multipolar spindle in NSCLCs and further sensitized NSCLCs to radiation treatment. CC is not typically required for normal cells, and thus CCi may be a more specific and perhaps less toxic therapy for NSCLCs. The potential of CCi to enhance IMT is under investigation. Citation Format: Hailun Wang, Katriana Nugent, ","PeriodicalId":271698,"journal":{"name":"Imaging, Radiation Oncology, Radiomics","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132586889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract IA31: Radiation therapy in lung cancer: Recent trends and future directions 摘要:肺癌放射治疗:近期趋势和未来方向
Imaging, Radiation Oncology, Radiomics Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-IA31
D. Gomez
{"title":"Abstract IA31: Radiation therapy in lung cancer: Recent trends and future directions","authors":"D. Gomez","doi":"10.1158/1557-3265.AACRIASLC18-IA31","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-IA31","url":null,"abstract":"Radiation techniques for lung cancer have evolved substantially over the past decade. While previously many patients were treated with 3D conformal therapy, with large uniform margins placed to estimate respiratory motion in the “average” tumor, patients are now simulated with sophisticated, real-time monitoring of internal motion such that treatment volumes can be individualized to maximize normal tissue sparing through image-guided radiation therapy (IGRT). In addition, many patients are now treated with intensity-modulated radiation therapy (IMRT), which has served to drastically improve conformality in select cases and increase the proportion of patients in which high doses are achievable. Concurrent with these advances, proton beam therapy (PBT) has been implemented in a limited number of centers, with the hope of utilizing the dosimetric distribution advantage of the Bragg Peak to further reduce toxicity. The role of PBT in both early-stage and locally advanced non-small cell lung cancer continues to be defined, as results from a phase II multicenter randomized trial predominantly in patients with stage II-III disease did not demonstrate superiority with PBT and concurrent chemotherapy when compared to similar regimens with IMRT. Finally, there have been much data produced with regard to dosing regimens. In early-stage disease, there has been increased implementation of stereotactic ablative body radiation (SABR), with prospective data emerging for both peripheral and central lesions. In the locally advanced setting, results from RTOG 0617 demonstrated no difference when comparing 60 Gy vs. 74 Gy in the setting of chemoradiation. There has also been a trend towards hypofractionation for patients who are unable to tolerate concurrent chemoradiation or those with oligometastatic disease, yet the benefit of hypofractionated radiation sequentially vs. combined modality treatment will need to be further assessed in prospective randomized trials, particularly in the era of immunotherapy. Citation Format: Daniel R. Gomez. Radiation therapy in lung cancer: Recent trends and future directions [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA31.","PeriodicalId":271698,"journal":{"name":"Imaging, Radiation Oncology, Radiomics","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126106488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书